As discussions around an updated government policy road map for the sector begin, the three main groups representing the innovative pharma industry in Japan have presented a united front in again calling for reforms to the country’s drug pricing and wider healthcare system.
The joint wish list puts the greatest emphasis on the creation and maintenance of an operating environment conducive to investment...






